Chikungunya Virus Infection Clinical Trial
Official title:
Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
This is a multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and immunogenicity of a 2-injection vaccine Chikungunya virus (CHIKV) virus-like particle vaccine (CHIKV VLP) in healthy adults.
This is a Phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and immunogenicity of a 2-injection vaccine regimen (Day 0 and 28) with Chikungunya virus (CHIKV) virus-like particle vaccine (CHIKV VLP, VRC-CHKVLP059-00-VP) in healthy adults ages 18-60 years old that reside in CHIKV endemic regions. The hypothesis is that the vaccine regimen is safe and induces a neutralizing antibody response to CHIKV. The primary objectives are to evaluate safety and tolerability of a 2-injection investigational vaccine regimen of VRC-CHKVLP059-00-VP at 20 mcg compared to placebo (PBS) in healthy adults in CHIKV endemic areas. The secondary objective is to evaluate neutralizing antibody response in vaccine recipients. The exploratory objectives relate to assessing incidence of CHIKV infection in vaccine and placebo recipients, as well as antigen-specific humoral and cellular immune responses during the study. The expected study duration per subject is approximately 72 weeks with intramuscular (IM) injections scheduled at Day 0 and Day 28. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02230163 -
Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins
|
Phase 1/Phase 2 | |
| Completed |
NCT04546724 -
Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
|
Phase 3 | |
| Terminated |
NCT04455919 -
Yoga for Chronic Chikungunya
|
N/A | |
| Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
| Active, not recruiting |
NCT04441905 -
Phase 1 Study of SAR440894 vs Placebo
|
Phase 1 | |
| Not yet recruiting |
NCT06028841 -
A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)
|
Phase 3 | |
| Completed |
NCT03028441 -
Phase I Trial of Measles Vectored Chikungungya Vaccine
|
Phase 1 | |
| Completed |
NCT03807843 -
Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
|
Phase 2 | |
| Completed |
NCT04909411 -
Consequences of a Maternal-fetal Chikungunya Virus Infection
|
N/A | |
| Completed |
NCT04786444 -
Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
|
Phase 3 | |
| Completed |
NCT02553369 -
Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection
|
N/A | |
| Recruiting |
NCT06106581 -
A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years
|
Phase 2 | |
| Recruiting |
NCT06007183 -
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
|
Phase 3 | |
| Completed |
NCT03635086 -
Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)
|
Phase 2 | |
| Completed |
NCT02861586 -
Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine
|
Phase 2 | |
| Active, not recruiting |
NCT04838444 -
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)
|
Phase 3 | |
| Completed |
NCT03483961 -
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
|
Phase 2 |